My Capital One Venture X comes with a free Priority Pass membership that gets me access to over 1,700 airport lounges, but ...

The FDA has granted priority review to an NDA for taletrectinib in the treatment of advanced ROS1-positive non–small cell ...

China National Medical Products Administration (NMPA) has granted acceptance and priority review for the new drug application ...

Verastem (VSTM) said the FDA has accepted for priority review its application for accelerated approval of its ...

Shares of Verastem surged after the company's new cancer treatment got priority review from regulators. The stock was up 46% at $5.37 on Tuesday. Shares are still down 35% since the start of the year.

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) under Priority Review for avutometinib, in combination with defactinib, for the treatment of adults with ...

Chimerix submitted a new drug application to the FDA seeking accelerated approval for dordaviprone to treat patients with ...

On December 20, 2024, the FDA granted accelerated approval to the combination of encorafenib (Braftovi), cetuximab (Erbitux), ...

The FDA granted priority review to taletrectinib in ROS1-positive advanced NSCLC, with a target decision date of June 2025.

Verastem Oncology said its treatment for recurrent low-grade serous ovarian cancer has been given priority review by the Food and Drug Administration. The new drug application for the treatment in ...

The NDA, which was completed in October 2024, has been granted Priority Review with a Prescription Drug User Fee Act (PDUFA) action date of June 30, 2025. In addition, the FDA has stated that it ...